Letters to the Editor

Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in Europe

Department of Medical and Surgical Sciences, University of Bologna, Bologna
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul
Department of Hematology, Catholic University of Leuven, Leuven
Hematology Department, University Hospital of Leon, IBIOLEON, Leon
Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY
MD Anderson Cancer Center, Houston, Texas
Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg
Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg
Hematology Department, Careggi Hospital, Florence
Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo
GSK, Stevenage
GSK, Zug
GSK, London
GSK, Stevenage
GSK, Upper Providence, PA
Syneos Health, Amsterdam
GSK, Upper Providence, PA
GSK, London
GSK, Neuchatel
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY
Haematologica Early view Jan 22, 2026 https://doi.org/10.3324/haematol.2025.289034